Nϵ-(carboxymethyl)-lysine, White Matter, and Cognitive Function in Diabetes Patients

Canadian Journal of Neurological Sciences

Volumn 43, Issue 4, 2016, Pages 518-522

  Zhang, Jian Hui ^a   Xu, Hong Zeng ^a   Shen, Qi Feng ^a   Lin, Yong Zhong ^a   Sun, Chang Kai ^a   Sha, Lin ^a   Ge, Yu Song ^a   Liu, Ying ^a   Wang, Chun ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Cognitive impairment; Diffusion tensor imaging; Hippocampal atrophy; Magnetic resonance imaging; N (Carboxymethyl) lysine; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; LYSINE DERIVATIVE; N EPSILON (CARBOXYMETHYL) LYSINE; UNCLASSIFIED DRUG; LYSINE; N(6)-CARBOXYMETHYLLYSINE;

AGED; ARTICLE; BRAIN ANALYSIS; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS CALLOSUM; DIABETIC PATIENT; DIFFUSION TENSOR IMAGING; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRACTIONAL ANISOTROPY; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HIPPOCAMPUS; HUMAN; IMAGE ANALYSIS; MALE; MINI MENTAL STATE EXAMINATION; MONTREAL COGNITIVE ASSESSMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE SCANNER; OCCIPITOFRONTAL FASCICULUS; PRIORITY JOURNAL; TEMPORAL LOBE; WHITE MATTER; ANALOGS AND DERIVATIVES; ANISOTROPY; BLOOD; CASE CONTROL STUDY; COGNITION DISORDERS; COMPLICATION; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; IMAGE PROCESSING; LEUKOENCEPHALOPATHIES; MENTAL HEALTH; NEUROPSYCHOLOGICAL TEST;

AGED; ANISOTROPY; CASE-CONTROL STUDIES; COGNITION DISORDERS; DIABETES MELLITUS, TYPE 2; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LEUKOENCEPHALOPATHIES; LYSINE; MALE; MENTAL STATUS SCHEDULE; NEUROPSYCHOLOGICAL TESTS;

EID: 84975720730     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/cjn.2015.398     Document Type: Article

References (35)

1. McCrimmon RJ, Ryan CM, Frier BM. Diabetes and cognitive dysfunction. Lancet. 2012;379:2291-9.
2. Munshi M, Grande L, Hayes M, et al. Cognitive dysfunction is associated with poor diabetes control in older adults. Diabetes Care. 2006;29:1794-9.
3. Biessels GJ, Deary IJ, Ryan CM. Cognition and diabetes: a lifespan perspective. Lancet Neurol. 2008;7:184-90.
4. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006;5:64-74.
5. Ryan JP, Fine DF, Rosano C. Type 2 diabetes and cognitive impairment: contributions from neuroimaging. J Geriatr Psychiatry Neurol. 2014;27:47-55.
6. Bozzali M, Cherubini A. Diffusion tensor MRI to investigate dementias: a brief review. Magn Reson Imaging. 2007;25: 969-77.
7. Hsu JL, Chen YL, Leu JG, et al. Microstructural white matter abnormalities in type 2 diabetes mellitus: a diffusion tensor imaging study. Neuroimage. 2012;59:1098-105.
8. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-20.
9. Southern L, Williams J, Esiri MM. Immunohistochemical study of N-epsilon-carboxymethyl lysine (CML) in human brain: relation to vascular dementia. BMC Neurol. 2007;7:35.
10. Horie K, Miyata T, Yasuda T, et al. Immunohistochemical localization of advanced glycation end products, pentosidine, and carboxymethyllysine in lipofuscin pigments of Alzheimer's disease and aged neurons. Biochem Biophys Res Commun. 1997;236:327-32.
11. Ikeda K, Higashi T, Sano H, et al. N (epsilon)-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry. 1996;35:8075-83.
12. Bar KJ, Franke S, Wenda B, et al. Pentosidine and N(epsilon)-(carboxymethyl)-lysine in Alzheimer's disease and vascular dementia. Neurobiol Aging. 2003;24:333-8.
13. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695-9.
14. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-98.
15. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412-4.
16. Hu S, He W, Liu Z, Xu H, Ma G. The accumulation of the glycoxidation product N(epsilon)-carboxymethyllysine in cardiac tissues with age, diabetes mellitus and coronary heart disease. Tohoku J Exp Med. 2013;230:25-32.
17. Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage. 2002;17:825-41.
18. Smith SM. Fast robust automated brain extraction. Hum Brain Mapp. 2002;17:143-55.
19. van Deutekom AW, Niessen HW, Schalkwijk CG, Heine RJ, Simsek S. Increased Nepsilon-(carboxymethyl)-lysine levels in cerebral blood vessels of diabetic patients and in a (streptozotocin-treated) rat model of diabetes mellitus. Eur J Endocrinol. 2008;158: 655-60.
20. Genuth S, Sun W, Cleary P, et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes. 2005;54:3103-11.
21. McCance DR, Dyer DG, Dunn JA, et al. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest. 1993;91:2470-8.
22. Smith SM, Jenkinson M, Johansen-Berg H, et al. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage. 2006;31:1487-505.
23. Last D, Alsop DC, Abduljalil AM, et al. Global and regional effects of type 2 diabetes on brain tissue volumes and cerebral vasoreactivity. Diabetes Care. 2007;30:1193-9.
24. van Harten B, de Leeuw FE, Weinstein HC, Scheltens P, Biessels GJ. Brain imaging in patients with diabetes: a systematic review. Diabetes Care. 2006;29:2539-48.
25. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med. 1995;46:223-34.
26. Furth AJ. Glycated proteins in diabetes. Br J Biomed Sci. 1997;54:192-200.
27. Yaffe K, Lindquist K, Schwartz AV, et al. Advanced glycation end product level, diabetes, and accelerated cognitive aging. Neurology. 2011;77:1351-6.
28. Takeuchi M, Yamagishi S. TAGE (toxic AGEs) hypothesis in various chronic diseases. Med Hypotheses. 2004;63:449-52.
29. Reijmer YD, Brundel M, de Bresser J, et al. Microstructural white matter abnormalities and cognitive functioning in type 2 diabetes: a diffusion tensor imaging study. Diabetes Care. 2013;36:137-44.
30. Kodl CT, Franc DT, Rao JP, et al. Diffusion tensor imaging identifies deficits in white matter microstructure in subjects with type 1 diabetes that correlate with reduced neurocognitive function. Diabetes. 2008;57:3083-9.
31. Yau PL, Javier D, Tsui W, et al. Emotional and neutral declarative memory impairments and associated white matter microstructural abnormalities in adults with type 2 diabetes. Psychiatry Res. 2009;174:223-30.
32. Falvey CM, Rosano C, Simonsick EM, et al. Macro-and microstructural magnetic resonance imaging indices associated with diabetes among community-dwelling older adults. Diabetes Care. 2013;36:677-82.
33. Gold SM, Dziobek I, Sweat V, et al. Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes. Diabetologia. 2007;50:711-9.
34. Chen HT, Lin HD, Won JG, et al. Cardiovascular autonomic neuropathy, autonomic symptoms and diabetic complications in 674 type 2 diabetes. Diabetes Res Clin Pract. 2008;82: 282-90.
35. Hsu WC, Chiu YH, Chen WH, Chiu HC, Liou HH, Chen TH. Simplified electrodiagnostic criteria of diabetic polyneuropathy in field study (KCIS No. 14). Neuroepidemiology. 2007;28:50-5.